244 related articles for article (PubMed ID: 10537964)
21. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
[TBL] [Abstract][Full Text] [Related]
22. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
[TBL] [Abstract][Full Text] [Related]
23. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
24. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
Palmer CS; Brunner E; Ruíz-Flores LG; Paez-Agraz F; Revicki DA
Arch Med Res; 2002; 33(6):572-80. PubMed ID: 12505105
[TBL] [Abstract][Full Text] [Related]
25. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.
Tunis SL; Croghan TW; Heilman DK; Johnstone BM; Obenchain RL
Med Care; 1999 Jul; 37(7):678-91. PubMed ID: 10424639
[TBL] [Abstract][Full Text] [Related]
26. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Tollefson GD; Sanger TM; Lu Y; Thieme ME
Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
[TBL] [Abstract][Full Text] [Related]
27. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
28. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
29. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
[TBL] [Abstract][Full Text] [Related]
30. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Sauriol L; Laporta M; Edwardes MD; Deslandes M; Ricard N; Suissa S
Clin Ther; 2001 Jun; 23(6):942-56. PubMed ID: 11440294
[TBL] [Abstract][Full Text] [Related]
32. The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
Am J Manag Care; 1999 Jul; 5(10 Suppl):S583-90. PubMed ID: 10539493
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Breier A; Hamilton SH
Biol Psychiatry; 1999 Feb; 45(4):403-11. PubMed ID: 10071708
[TBL] [Abstract][Full Text] [Related]
34. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
[TBL] [Abstract][Full Text] [Related]
35. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.
Beasley CM; Hamilton SH; Crawford AM; Dellva MA; Tollefson GD; Tran PV; Blin O; Beuzen JN
Eur Neuropsychopharmacol; 1997 May; 7(2):125-37. PubMed ID: 9169300
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
[TBL] [Abstract][Full Text] [Related]
37. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
38. Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Peuskens J; Gillain B; De Graeve D; Van Vleymen B; Albert A
Eur Psychiatry; 2009 Apr; 24(3):154-63. PubMed ID: 19118983
[TBL] [Abstract][Full Text] [Related]
39. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
40. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
